MyMD Pharmaceuticals, Inc.

MYMD

US62856X2018

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.86 ^USD	+11.72%		+27.11%	-63.15%

Apr. 18	MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	CI
Apr. 09	Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	MT

MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	Apr. 18	CI
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09	MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	Apr. 09	MT
Top Premarket Gainers	Apr. 09	MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	Mar. 05	MT
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split	Feb. 13	MT
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	Dec. 06	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	23-10-19	CI
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	23-10-04	CI
MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) dropped from S&P Global BMI Index	23-09-18	CI
Insider Buy: Mymd Pharmaceuticals	23-08-24	MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
MyMD Pharmaceuticals Says Its Investigational New Drug Application for Rheumatoid Arthritis Treatment Gets FDA Acceptance	23-08-14	MT
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis	23-08-14	CI
MyMD Pharmaceuticals' MYMD-1 Study Shows Positive Results for Age-Related inflammation Drug; Shares Rise	23-07-31	MT
Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty	23-07-31	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
MyMD Pharmaceuticals Says Phase 2 Trial of Treatment for Sarcopenia, Frailty Shows No Safety Issues	23-04-12	MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
MyMD Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Mymd Pharmaceuticals, Inc. to Present Data from Preclinical Study of its MYMD-1 Product Candidate in A Rheumatoid Arthritis (Ra) Model at the 2023 Society of Toxicology Annual Meeting	23-03-20	CI
MyMD Pharmaceuticals' Supera-CBD Determined by US Drug Enforcement Administration as Not Controlled Substance	23-03-02	MT
MyMD Pharmaceuticals, Inc. Announces U.S. Drug Enforcement Administration Determines Supera-CBD Is Not A Controlled Substance or Listed Chemical	23-03-02	CI

Chart MyMD Pharmaceuticals, Inc.

Duration

Period

More charts

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MYMD PHARMACEUTICALS, INC.	-63.15%	6.17M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.28%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-9.98%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B